Lenvatinib + farletuzumab ecteribulin for adenocarcinoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 9 Mar 2020: Trial registered, NCT04300556
  2. 6 Aug 2020: Trial started, NCT04300556

The trials

NCT04300556: A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

State
Under way
Phase
Phase 1 and Phase 2
People
182 planned
Started
6 Aug 2020
Primary completion
8 Aug 2030
Arms
Dose Optimization Part B: Farletuzumab ecteribulin + Lenvatinib
Results
None posted
  1. 9 Mar 2020: Trial registered
  2. 6 Aug 2020: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.